Scientists Finally Found a Way to Target a Cancer Gene Once Called Undruggable
Decades of taxpayer-funded work led to drugs that wedge into the RAS protein.

Not Dead Yet · Francis CollinsIn October, former U.S. Senator Ben Sasse, who has cancer, told geneticist Francis Collins that he had undergone major liver surgery. He was nine months past being told he had only three months to live.
Sasse said he felt grateful for the downstream effects of genome research that had opened new paths for cancer treatment. Collins led the public Human Genome Project and then ran the country’s main medical research agency from 2009 through 2021.
Sasse had asked where that genome knowledge leads next, for new treatments in general and for drugs used in combination. Collins answered with the story of one cancer gene, RAS, and how decades of taxpayer-supported work turned it into a drug target. Collins pointed to Sasse’s treatment as an example of that progress.
In 1982, when Collins was a postdoctoral researcher, scientist Bob Weinberg published a landmark paper. He had taken DNA from a human tumor, broken it into little pieces, and put those pieces into normal cells. Some turned malignant, showing something in that DNA could transform a healthy cell into a cancer cell. That something was RAS.
Researchers soon found closely related versions, known as H-RAS, KRAS, and NRAS. Sasse said his own tumor carried a form called KRAS G12V, a specific misspelling in the KRAS gene. Different misspellings respond to different drugs, so identifying the exact change has become central to choosing treatment.
At first, scientists in the 1980s thought RAS would quickly lead to a drug. Instead, Collins said, “RAS turned out to be undruggable,” the word researchers used for the next 20 years. Drug companies largely gave up, while taxpayer-funded work through the National Institutes of Health kept going, including a dedicated RAS program at the National Cancer Institute led by Frank McCormick.
The turn came from Kevin Shokat, a researcher at the University of California, San Francisco. The RAS protein looks like a greasy ball with little surface for a drug to grab, but Shokat found a deep pocket where a drug could fit. Collins said Shokat “finally figured out there was a way to wedge a drug into this sort of greasy ball.”
Then scientists at a company called Revolution Medicines developed a more dramatic approach using a molecular glue, a second molecule that holds the drug onto the protein. Collins said the new approach “also depended upon two decades of deeply worked out, hard fought, lots of failures, public science.”
He added, “People don’t understand, I think, how long it takes to develop something that then suddenly seems like a miracle, but it was standing on a lot of shoulders.”
Collins is now trying to make that history better known through his nonprofit, Discovery Lives in Us, his effort to explain that breakthroughs depend on long term cooperation among government, companies, patient groups, and donors. He argues that the United States led the world in that model for decades, but that American public support for that work is now pulling back.
Questions people ask
Why was RAS so hard to target?
Most drugs work by fitting into grooves on a protein’s surface, but RAS is unusually smooth and round. It also grips its fuel molecule very tightly, leaving little opening for a blocker. That shape is why companies concluded there was nowhere useful for a drug to attach.
How does a molecular glue drug work?
A molecular glue does not attack the cancer protein by itself. It acts as a bridge that helps a drug molecule stick to the target and stay in place long enough to block it. For RAS, that extra hold made it possible to inhibit a protein that previously slipped free.
Why do researchers want to use RAS drugs in combination?
A single drug often shrinks a tumor for a time, and then the cancer finds a workaround and starts growing again. Using two or more drugs together can block several growth paths at once or help the immune system join the attack. That is why researchers now test RAS blockers paired with other treatments.

